{"analyses":[{"ciLowerLimit":"0.564","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.775","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.661","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Here 'NA' represents that upper limit of 95% CI was not estimable due to lesser number of events.","groupId":"OG000","lowerLimit":"48.23","upperLimit":"NA","value":"53.32"},{"groupId":"OG001","lowerLimit":"33.54","upperLimit":"39.95","value":"36.53"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"597"},{"groupId":"OG001","value":"602"}],"units":"Participants"}],"description":"Overall survival was defined as the time from randomization to date of death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received abiraterone acetate tablet at a total dose of 1000 milligram (mg) plus 5 mg capsule of prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of androgen deprivation therapy (ADT) was administered.","id":"OG000","title":"Abiraterone Acetate+Prednisone+ADT"},{"description":"Participants received placebo matched to abiraterone acetate plus prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of ADT was administered.","id":"OG001","title":"Placebo + ADT"}],"paramType":"MEDIAN","populationDescription":"ITT analysis set included all subjects randomized into the study and who were classified according to their assigned treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"Up to 66 months","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}